勃林格殷格翰收购Evax，旨在应对马匹过敏问题-动脉网

Boehringer Ingelheim acquires Swiss biotech in bid to combat equine allergies

D-Pharm 等信源发布 2026-08-20 12:34



可切换为仅中文







Boehringer Ingelheim that it has acquired Evax AG, a Swiss biotech company focused on equine health. Founded more than a decade ago at the University of Zurich, Evax has been exploring the use of

勃林格殷格翰宣布已收购瑞士生物技术公司 Evax AG，该公司专注于马匹健康。Evax 于十多年前在苏黎世大学创立，一直致力于探索利用

therapeutic vaccines

治疗性疫苗

to address significant unmet needs in horses, particularly for the treatment of allergic

以解决马匹尚未满足的重大需求，特别是用于治疗过敏

skin diseases

皮肤病

。

“We’re excited to have the potential to offer horse owners the first innovative therapeutic option for allergic skin diseases targeting the underlying cause of the disease. This may result in a longer duration of action, better treatment outcomes, and increased convenience and compliance,” said Saskia Kley, Global Head of Equine for Boehringer Ingelheim..

“我们很兴奋有可能为马主提供首个针对过敏性皮肤病根本病因的创新治疗选择。这可能带来更长的作用持续时间、更好的治疗效果，以及更高的便利性和依从性。”勃林格殷格翰公司全球马业务负责人 Saskia Kley 表示。

Allergies and dermatologic conditions in horses are common and have a significant impact on their health and well-being yet are very challenging to treat. Current options for management of these conditions are often time-consuming and provide only temporary relief (e.g., shampoos and topical treatments), while some therapies may be associated with significant safety concerns (e.g.

马的过敏性疾病和皮肤病很常见，对其健康与福祉有重大影响，但治疗极具挑战性。目前针对这些病症的管理方案往往耗时较长，且仅能提供暂时缓解（例如使用洗发剂和局部外用药物），而某些疗法可能存在显著的安全性隐患（例如

corticosteroids). Therapeutic vaccines incorporating virus-like particles are designed to induce the horse’s immune system to produce neutralizing antibodies, treating the underlying cause of the disease..

皮质类固醇）。 incorporating 病毒样颗粒的治疗性疫苗旨在诱导马的免疫系统产生中和抗体，从而治疗疾病的根本病因。

“We’re excited to join Boehringer Ingelheim Animal Health, and tap their innovation, supply and commercial expertise, as we advance through the next phases of providing novel therapeutic treatment options in areas of unmet need for horses,” said Dr. Antonia Gabriel, CEO and Founder of Evax.

“我们很高兴加入勃林格殷格翰动物保健公司，并借助其在创新、供应链和商业化方面的专业知识，以推进我们在马匹未满足医疗需求领域提供新型治疗方案的下一阶段工作。”Evax 公司首席执行官兼创始人安东尼娅·加布里埃尔博士表示。

Boehringer Ingelheim has been pursuing therapeutic vaccines for many years, including through its collaboration with and subsequent acquisition of Saiba Animal Health in 2024.

勃林格殷格翰多年来一直在推进治疗性疫苗的研发，包括通过与Saiba Animal Health合作并于2024年收购该公司。

“The acquisition of Evax advances our strategy to drive breakthrough innovation in our preventive and therapeutic portfolio. Virus-like particle technology represents a truly innovative approach in animal health, with the potential to address areas of high unmet medical need, including chronic diseases in pets and allergy-related disorders in horses.

“收购Evax推进了我们在预防和治疗产品组合中推动突破性创新的战略。病毒样颗粒技术代表了动物健康领域一种真正创新的方法，有望解决尚未满足的高医疗需求领域，包括宠物的慢性疾病和马匹的过敏相关疾病。”

Based on our research to date, we believe that this technology can play an important role in improving animal health and wellbeing,” said Knut Elbers, Head of Global Innovation, Animal Health at Boehringer Ingelheim..

“基于我们迄今为止的研究，我们相信这项技术可以在改善动物健康和福祉方面发挥重要作用。”勃林格殷格翰动物健康全球创新负责人克努特·埃尔伯斯表示。

Terms of the transaction were not disclosed.

交易条款未予披露。

https://www.bionity.com/en/news/1189616/boehringer-ingelheim-acquires-swiss-biotech-in-bid-to-combat-equine-allergies.html

Amferia closes €1,2 million investment to combat resistant bacterial infections

Amferia 完成120万欧元融资，用于对抗耐药性细菌感染

'Bacterial infections are likely to surpass cancer and heart disease as a number one cause of human deaths in the future...'

“未来，细菌感染可能会超越癌症和心脏病，成为人类死亡的首要原因……”

Read news

阅读新闻

Most read news

阅读最多的新闻